Medizinische Universität Graz - Research portal
Selected Publication:
Haselsberger, K; Radner, H; Pendl, G.
Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase.
Cancer Lett. 1998; 131(1):109-111
Doi: 10.1016%2FS0304-3835%2898%2900206-7
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Haselsberger Klaus
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Boron neutron capture therapy (BNCT) represents a highly promising therapeutic alternative for the treatment of the most common malignant brain tumor, glioblastoma multiforme. Both the efficacy and safety of BNCT are greatly dependent on the pattern of 10B biodistribution. The present study investigates the influence of systemic hyaluronidase applied in combination with Na2B12H11SH (BSH), a boron carrier used in current clinical trials. The application of hyaluronidase was associated with a statistically significant improvement in the tumor/blood boron concentration ratio which suggests that hyaluronidase is capable of enhancing the therapeutic potential of BSH.
- Find related publications in this database (using NLM MeSH Indexing)
- Boron - pharmacokinetics
- Chemotherapy, Adjuvant - pharmacokinetics
- Clinical Trials - pharmacokinetics
- Glioblastoma - therapy
- Humans - therapy
- Hyaluronoglucosaminidase - therapeutic use
- Neutron Capture Therapy - therapeutic use
- Tissue Distribution - therapeutic use
- Find related publications in this database (Keywords)
- Boron Neutron Capture Therapy
- Bsh
- Glioblastoma
- Hyaluronidase